Today: 19 May 2026
Nike stock jumps 4% after CEO Elliott Hill discloses $1 million share buy
31 December 2025
1 min read

Nike stock jumps 4% after CEO Elliott Hill discloses $1 million share buy

NEW YORK, December 31, 2025, 16:39 ET — After-hours

  • Nike shares outperformed the broader market in late trade after a CEO insider-buying filing.
  • Elliott Hill reported buying 16,388 shares at about $61.10 each, an SEC filing showed.
  • Investors are watching for clearer signs of margin stabilization and demand improvement into 2026.

Nike, Inc. (NKE) shares rose 4.2% to $63.71 in after-hours trading on Wednesday after a regulatory filing showed CEO Elliott Hill bought about $1 million of company stock. Nike traded between $61.96 and $64.19 during the session and volume topped 35 million shares. The S&P 500 ETF SPY fell 0.7% and the consumer-discretionary ETF XLY slid 0.8%.

Insider buying can sway sentiment because executives are seen as having a clearer view of the business than outside investors. Nike is down about 19% for the year, and Guggenheim analyst Simeon Siegel said the purchases were encouraging even with pressure from falling margins and weaker China sales, Reuters reported.

The disclosure arrives as traders look for signs that Nike’s turnaround is starting to take hold after a volatile December. Investors have focused on the pace of inventory cleanup and whether demand is stabilizing across key regions ahead of the next quarterly update.

In a Form 4 filed with the U.S. Securities and Exchange Commission on Tuesday, Hill reported buying 16,388 Class B shares on Dec. 29 at a weighted-average $61.10. The filing said the buys were executed at prices ranging from $61.09 to $61.10 and lifted his direct holdings to 241,587 shares. It also noted that, under company policy, market transactions are permitted only during a post-earnings trading window unless done under 10b5-1 plans—pre-set trading instructions designed to limit the risk of trading on material non-public information.

Nike’s last results showed why investors have been cautious. In its Dec. 18 release for fiscal second-quarter results, the company said revenue rose 1% to $12.4 billion while net income fell 32% to $792 million, and gross margin—a key profitability measure—fell 300 basis points, or three percentage points, to 40.6% on higher tariffs in North America. “We are making the shifts required to position our portfolio for a full recovery,” Chief Financial Officer Matthew Friend said. Nike Investors

The stock fell about 11% after those results, Barron’s reported, before stabilizing into year-end.

Traders say the next test is whether Nike can lift gross margin without leaning on heavy discounts. Updates on inventory levels and demand in Greater China remain central to that call.

The rebound on insider buying underlines how sensitive the stock remains to incremental signals about the turnaround. The shares have tended to move sharply this year on any change in expectations for margins and regional demand.

Nike has not announced the date for its next earnings report. The next release is expected around March 19, according to Zacks Investment Research.

With liquidity thinning late in the year, traders will watch whether Wednesday’s move holds once regular volumes return in January. For Nike, any follow-through will hinge on evidence that margins are stabilizing and regional demand trends are improving.

Stock Market Today

  • JPMorgan Warns Nifty Could Slide to 20,500 Amid Iran Tensions and Oil Price Risks
    May 19, 2026, 7:48 AM EDT. JPMorgan warned that the Nifty index might fall to 20,500 points amid fears of a renewed war in Iran and a potential oil price shock. The bank highlighted risks to earnings in the current fiscal's first quarter due to rising input costs and currency depreciation. These factors could pressure Indian equities as market sentiment turns cautious on geopolitical uncertainties and inflation risks.

Latest articles

MetaVia Stock Wakes Up Before the Bell as Obesity-Drug Data Gets an ADA Slot

MetaVia Stock Wakes Up Before the Bell as Obesity-Drug Data Gets an ADA Slot

19 May 2026
Diploma PLC shares rose 4.75% to 6,940p after the company raised its 2026 outlook, citing strong demand and a 17% rise in first-half revenue to £851.1 million. Adjusted operating profit climbed 33% to £208.9 million, and the interim dividend increased 5% to 19.1p. The Controls division posted 26% organic growth. Diploma completed 15 acquisitions worth about £310 million in the past year.
Zeta Global Pops Again as Traders Eye OpenAI Ad Deal

Zeta Global Pops Again as Traders Eye OpenAI Ad Deal

19 May 2026
Zeta Global shares rose 3.4% to $19.85 in premarket trading Tuesday after CEO David Steinberg announced an advertising agreement with OpenAI at a JPMorgan conference. The stock had closed up 11.6% at $19.19 on Monday, trading over 17 million shares. Bank of America reinstated coverage with a Buy rating and $24 target. Zeta recently reported first-quarter revenue up 50% year-over-year to $396 million.
Home Depot Earnings Show Housing Stress for Wall Street

Home Depot Earnings Show Housing Stress for Wall Street

19 May 2026
Home Depot reported first-quarter sales of $41.8 billion, up 4.8%, beating estimates, but comparable sales rose just 0.6%, missing analyst forecasts. Net earnings fell to $3.3 billion from $3.4 billion a year earlier. The company kept its 2026 outlook unchanged. Shares edged higher in premarket trading.

Popular

Micron Stock Is Falling Hard As Samsung’s Strike Fight Tests The AI Memory Boom

Micron Stock Is Falling Hard As Samsung’s Strike Fight Tests The AI Memory Boom

18 May 2026
Micron Technology shares dropped 6.4% to $678.30 by early afternoon Monday, reversing an opening surge and hitting a session low as investors pulled back from semiconductor stocks. The decline followed a 6.6% fall Friday and came amid broader chip sector losses, with the Philadelphia semiconductor index down over 2%. Samsung and its union are set to resume talks Tuesday to avert a strike that could disrupt 3% of global memory-chip output.
Meta stock slips after-hours as scam-ad scrutiny mounts, Manus AI deal draws focus
Previous Story

Meta stock slips after-hours as scam-ad scrutiny mounts, Manus AI deal draws focus

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop